The NLPR3 inflammasome and obesity-related kidney disease

Ben Ke a, Wen Shen b, Xiangdong Fang a, *, Qinghua Wu b, *

a Department of Nephrology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China
b Department of Cardiovascular Medicine, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China

Received: April 6, 2017; Accepted: June 14, 2017

Abstract

Over the past decade, the prevalence of obesity has increased, accompanied by a parallel increase in the prevalence of chronic kidney disease (CKD). Mounting evidence suggests that high body mass index (BMI) and obesity are important risk factors for CKD, but little is known about the mechanisms of obesity-related kidney disease (ORKD). The NLPR3 inflammasome is a polyprotein complex that plays a crucial role in the inflammatory process, and numerous recent studies suggest that the NLPR3 inflammasome is involved in ORKD development and may serve as a key modulator of ORKD. Moreover, inhibiting activation of the NLPR3 inflammasome has been shown to attenuate ORKD. In this review, we summarize recent progress in understanding the link between the NLPR3 inflammasome and ORKD and discuss targeting the NLPR3 inflammasome as a novel therapeutic approach for ORKD.

Keywords: NLPR3 inflammation • obesity-related kidney disease • mitochondrial dysfunction • endoplasmic reticulum stress • inflammation

Introduction

Obesity has become a serious public health problem worldwide. According to data from the US Centers for Disease Control and Prevention, only approximately 15% of the American population was obese in 1988, which is defined as having a BMI >30 kg/m² [1]. However, more than 25% of the adult population was overweight in 42 states, and more than 30% of the population was obese in 13 states in 2012 [1]. In 2014, more than 35% of American adults (78 million) and 17% of children (12.5 million) were obese [2]. Currently, over 600 million adults (>18 years) are obese worldwide [3], and the increasing prevalence of obesity has significant implications for cardiovascular disease and CKD. Higher BMI is associated with the presence and development of proteinuria in individuals without kidney disease [4–7]. Furthermore, numerous large population-based studies have shown that higher BMIs are associated with the presence and development of a low estimated glomerular filtration rate (GFR), rapid loss of estimated GFR over time [8] and end-stage renal disease [9]. Elevated BMI and obesity have been shown to be associated with rapid CKD progression in patients with pre-existing CKD [10].

The NLPR3 inflammasome is an approximately 700 kD polyprotein complex that plays a crucial role in the inflammatory process [11]. This inflammasome is associated with the apoptosis-associated speck-like protein that contains a caspase recruitment domain (ASC), which recruits caspase-1 and induces its activation. Caspase-1 is known as an IL-1β-converting enzyme to process pro-IL-1β into its mature IL-1β form and induce its secretion. Inhibiting activation of the NLPR3 inflammasome has been shown to attenuate ORKD. In this review, we summarize recent progress in understanding the link between the NLPR3 inflammasome and ORKD and discuss targeting the NLPR3 inflammasome as a novel therapeutic approach for ORKD.

Keywords: NLPR3 inflammation • obesity-related kidney disease • mitochondrial dysfunction • endoplasmic reticulum stress • inflammation

Introduction

Obesity has become a serious public health problem worldwide. According to data from the US Centers for Disease Control and Prevention, only approximately 15% of the American population was obese in 1988, which is defined as having a BMI >30 kg/m² [1]. However, more than 25% of the adult population was overweight in 42 states, and more than 30% of the population was obese in 13 states in 2012 [1]. In 2014, more than 35% of American adults (78 million) and 17% of children (12.5 million) were obese [2]. Currently, over 600 million adults (>18 years) are obese worldwide [3], and the increasing prevalence of obesity has significant implications for cardiovascular disease and CKD. Higher BMI is associated with the presence and development of proteinuria in individuals without kidney disease [4–7]. Furthermore, numerous large population-based studies have shown that higher BMIs are associated with the presence and development of a low estimated glomerular filtration rate (GFR), rapid loss of estimated GFR over time [8] and end-stage renal disease [9]. Elevated BMI and obesity have been shown to be associated with rapid CKD progression in patients with pre-existing CKD [10].

The NLPR3 inflammasome is an approximately 700 kD polyprotein complex that plays a crucial role in the inflammatory process [11]. This inflammasome is associated with the apoptosis-associated speck-like protein that contains a caspase recruitment domain (ASC), which recruits caspase-1 and induces its activation. Caspase-1 is known as an IL-1β-converting enzyme to process pro-IL-1β into its mature IL-1β form and induce its secretion. Inhibiting activation of the NLPR3 inflammasome has been shown to attenuate ORKD. In this review, we summarize recent progress in understanding the link between the NLPR3 inflammasome and ORKD and discuss targeting the NLPR3 inflammasome as a novel therapeutic approach for ORKD.
release, leading to inflammation and tissue damage [12]. Inflammasomes are reportedly present in podocytes, mesangial cells and intercalated cells in human kidneys [12, 13] although some controversy regarding inflammasome location remains [14]. Recently, numerous studies have shown the NLRP3 inflammasome to be involved in the onset of kidney disease, including diabetic nephropathy, IgA nephropathy, crystal-induced nephropathy and ORKD [12, 15, 16]. This review focuses on the role of the NLRP3 inflammasome in the development and progression of ORKD, which may provide a novel therapeutic strategy for ORKD treatment.

Potential mechanisms of ORKD

Obesity has long been associated with kidney diseases [17], including glomerulopathies, nephrolithiasis and poor renal graft survival. ORKD is essentially single-nephron hyperfiltration caused by the ratio of nephrons to body mass being reduced, and it has been recognized as a distinct entity characterized by glomerulomegaly, progressive glomerulosclerosis and renal functional decline [18]. While the exact mechanisms by which obesity worsens or causes CKD remain unclear, adiposity is known to cause kidney injury (Fig. 1). Some deleterious renal consequences of obesity may be mediated by downstream co-morbidity conditions, such as diabetes mellitus or hypertension, but adiposity has been shown to directly impact the kidneys by inducing the production of adiponectin [19], leptin [20] and resistin [21], and by disrupting gut microbiota [22]. These components activate the renin–angiotensin–aldosterone system [23], mitochondrial dysfunction [24], endoplasmic reticulum stress [25], inflammation [2], and increase the production of insulin and insulin resistance [26]. Thus far, obesity, especially morbid obesity, is believed to induce afferent vasodilation to augment the glomerular filtration rate, or more specifically, nephron hyperfiltration [27]. If glomerular autoregulation is impaired, systemic blood pressure can be transmitted to the glomerular capillaries, leading to barotrauma. Glomerular capillary dilation may increase barotrauma susceptibility, which would require podocytes to cover a larger surface, thereby leading to proteinuria [27].

Overweight and obesity are associated with hemodynamics, which manifests as nephron hyperfiltration [28]. He et al. found renal hemodynamic changes in early-stage obesity-related nephropathy in children [29], and Anastasio et al. found that a modified hemodynamic response to a protein meal may be the earliest hallmark of future kidney dysfunction in obese subjects [30]. Moreover, obesity is a status of systemic inflammation, which leads to aberrant renal perfusion [31]. In mice adipose tissue, the NLRP3 inflammasome was shown to promote high-fat diet (HFD)-induced inflammation [32], which may cause or worsen ORKD. Therefore, the NLRP3 inflammasome is associated with various cell types inside and outside the kidney in ORKD.

Diabetes mellitus, especially type 2 diabetes mellitus (T2DM), is a classic risk factor for ORKD [27], and the role of sodium-glucose cotransporter-2 (SGLT-2) in diabetic nephrology has recently attracted attention. SGLT-2, a member of the sodium-glucose transporter family, regulates renal glucose reabsorption in the proximal tubule [33] and reportedly drives the deactivation of tubuloglomerular feedback and hyperglycaemia-induced glomerular hyperfiltration [34], which is obviously aggravated by concomitant obesity. Furthermore, SGLT2 inhibitors increase the delivery of fluid and electrolytes to the macula densa, thereby activating tubuloglomerular feedback and increasing tubular back pressure, which mitigates glomerular hyperfiltration, reduces oxygen demand in the kidney and lessens albuminuria [34]. Therefore, SGLT2 may play an active role in ORKD. Ye et al. found that SGLT-2 inhibition with dapagliflozin reduced activation of the NLRP3/ASC inflammasome in T2DM mice [35]. Unfortunately, literature on the relationship between SGLT-2 and the NLRP3 inflammasome in ORKD is lacking.

Fig. 1 Adiposity leads to kidney injury. Schematic representation of the processes by which adiposity contributes to kidney injury.
The NLRP3 inflammasome and the renin–angiotensin–aldosterone system

The renin–angiotensin–aldosterone system (RAAS), known for its role in regulating blood pressure, fluids and electrolyte balance, plays an active role in ORKD. In addition, the RAAS is involved in many physiological and pathological processes, including tissue growth; hypertrophy; inflammation; and glucose, lipid and energy metabolism [36]. A RAAS blockade was shown to be highly effective in retarding the progression of renal disease in human and experimental animals [37], and increased RAAS activity, predominantly in visceral adipose tissue, is a characteristic of obesity [38]. Moreover, expression of all the RAAS components, including angiotensinogen (AGT), angiotensin-converting enzyme (ACE), renin, and the Ang II type 1 (AT1) and type 2 (AT2) receptors [39], has been detected in primary cultured adipocytes, human adipose tissue and commonly used rodent models. Furthermore, Ang II overexpression in adipose tissue and imbalance between the activated AT1 and AT2 receptor-mediated effects were shown to contribute to ORKD [40]. In addition, RAAS activation has been shown to promote the secretion of aldosterone, which leads to renal damage [41].

The RAAS may promote ORKD by activating the NLRP3 inflammasome (Fig. 2), as Wang et al. found that an RAS blockade using the renin inhibitor aliskiren prevented up-regulation of the NLRP3 inflammasome component ASC and inhibited caspase-1 activation and subsequent IL-1β processing and release [42]. Moreover, NLRP3 deletion was shown to protect tubular epithelial cells (TECs) from Ang II-triggered mitochondrial dysfunction and NLRP3 inflammasome activation. Thus, Ang II induces NLRP3 inflammasome activation, which is mediated by mitochondrial dysfunction, in TECs [43]. Furthermore, mitochondrial dysfunction was shown to cause the production of reactive oxygen species (ROS), which mediate NLRP3 inflammasome activation and contribute to aldosterone-induced renal tubular cell injury [44]. A recent study showed that Ang II could induce NLRP3 inflammasome activation through endoplasmic reticulum stress (ERS), which is a physiological or pathological condition caused by glucose deprivation, hypoxia, viral infection, or the Ang II-induced overexpression of NLRP3, ASC, caspase-1, IL-1β and IL-18 [45]. Eventually, NLRP3 inflammasome activation contributes to aldosterone-induced renal injury [46].

Epithelial–mesenchymal transition (EMT) is a process through which the renal epithelial phenotype is transformed into a mesenchymal phenotype in response to cell damage, leading to (ECM) accumulation and myofibroblast production, which is the key effector in the synthesis and deposition of the ECM complex [47]. On one hand, NLRP3 activation in TECs was shown to drive the EMT during progressive renal fibrosis [48], as Nlrp3−/− mice displayed reduced tubular injury and interstitial fibrosis upon unilateral ureteral ligation compared with wild-type animals [48]. On the other hand, Ang II was shown to induce hepatocyte EMT by promoting the NOX-derived, H2O2-activated NLRP3 inflammasome/IL-1β/Smad pathway [49]. Although Ang II induces NLRP3 inflammasome activation, little is known about the impact of the NLRP3 inflammasome on the RAAS.

Mitochondria participate in numerous cellular functions, including ion homeostasis, heme and steroid synthesis, calcium signalling and apoptosis [50]. The prominent role of this organelle is to generate energy for cellular metabolism using the oxidative phosphorylation system. Emerging evidence suggests that dysfunctional mitochondria play a primary role in the development of CKD and comorbidities related to CKD [50]. Mitochondrial dysfunction is reportedly involved in obesity and obesity-related disorders [24, 51] and can initiate autophagy, a cellular degradation pathway essential for survival, to remove dysfunctional mitochondria and maintain cellular homeostasis [52]. Yamamoto et al. found that autophagy ablation exaggerated HFD-induced mitochondrial dysfunction and inflammasome activation and proposed that HFD-impaired autophagic flux contributes to kidney lipotoxicity [53]. Moreover, protected mitochondria have been shown to overcome lipotoxicity in the kidney [25]. Considering these studies, a close relationship between mitochondrial dysfunction and ORKD was determined to exist [54].

Mitochondrial dysfunction may occur prior to NLRP3 activation in the development of ORKD (Fig. 3), and mitochondrial dysfunction can directly activate the NLRP3 inflammasome [43] by itself or indirectly activate the NLRP3 inflammasome via ROS production [44]. Meanwhile, NLRP3 proteins that are localized in mitochondria induce

![Fig. 2](image_url) Obesity promotes the production of Ang II, which activates the NLRP3 inflammasome via mitochondrial dysfunction or ERS. The NLRP3 inflammasome then induces renal injury via aldosterone.

---

*Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.*
ROS via Smad independent of the inflammasome [55], which may amplify NLRP3 inflammasome activation. Moreover, mitochondria-derived oxidative stress can induce mitochondrial dysfunction [56], which promotes further NLRP3 inflammasome activation. After being activated, the NLRP3 inflammasome may cause proteinuria-induced renal tubular injury and promote the TGF-β-induced alteration of the proximal tubular cell phenotype to induce ORKD [57, 58].

NLRP3 inflammasome activation may cause mitochondrial damage in ORKD (Fig. 3) [59], suggesting that mitochondrial damage might be the consequence rather than the cause of inflammasomal activation [60]. Moreover, ROS scavengers, such as N-acetyl-L-lysine (NAC), block the transcription of NLRP3 and pro-IL-1β but do not affect the direct activation of NLRP3 by classical NLRP3 agonists [61]. Furthermore, NLRP3 deletion was shown to protect against renal injury via inhibiting mitochondrial dysfunction [58], suggesting that the NLRP3 inflammasome can induce mitochondrial dysfunction to exacerbate ORKD. Further studies are needed to understand how mitochondrial dysfunction and danger signals derived from damaged mitochondria affect NLRP3 inflammasome activation in ORKD.

Whether mitochondrial dysfunction induces NLRP3 inflammasome activation remains controversial. Sadatomi et al. showed that mitochondrial function was required for extracellular ATP-induced NLRP3 inflammasome activation [62], and extracellular ATP has been shown to induce the loss of mitochondrial membrane potential and mitochondrial fragmentation in a manner different than that of other stimuli in primary mouse macrophages [63]. Carbonyl cyanide m-chlorophenyl hydrazone (CCCP), an uncoupler, and antimycin A, an inhibitor of the mitochondrial electron transport chain, could inhibit the release of IL-1β induced by ATP but not by other stimuli [64]. CCCP could not inhibit the ATP-induced generation of ROS and cell death, both of which are known to promote IL-1β release, but could inhibit the ATP-induced activation of caspase-1, a component of the NLRP3 inflammasome [64]. These results suggest that mitochondrial function is required specifically for ATP-induced NLRP3

---

**Fig. 3** The role of the NLRP3 inflammasome in ORKD development. First, mitochondrial dysfunction activates the NLRP3 inflammasome directly by itself or indirectly by increasing ROS production. Second, ERS activates the NLRP3 inflammasome either in response to ROS or by inducing the production of TXNIP, which is released from TRX and binds to NLRP3 to induce NLRP3 inflammasome activation. ERS amplifies the NLRP3 inflammasome by enabling Ca²⁺ mobilization from the endoplasmic reticulum, which can be modulated via the C/EPB homologous protein. Furthermore, TLR4 and the Ca²⁺-dependent MAPK-JNK pathway may activate the NLRP3 inflammasome.
inflammasome activation. In contrast to many previous reports that dysfunctional mitochondria promote NLRP3 inflammasome activation, functionally intact mitochondria appear to be required for NLRP3 inflammasome activation, depending on the stimulus [62].

The NLRP3 inflammasome and endoplasmic reticulum stress

Endoplasmic reticulum stress plays a vital role in the development of CKD [65, 66], and inhibition of ERS has been shown to alleviate the progression of CKD [67–69]. Similarly, recent studies have confirmed that ERS plays a specific role in the development of ORKD by inducing mitochondrial dysfunction [25, 70], and inhibition of ERS can effectively attenuate ORKD [70, 71]. However, the mechanism by which ERS contributes to ORKD remains unclear.

The ERS/NLRP3 inflammasome axis may play a key role in the development of ORKD although few studies have reported their relationship in ORKD (Fig. 3). Li et al. found a significant overlap of NLRP3 with the ER marker calreticulin in renal proximal tubular cells, suggesting a crucial role of ERS in inflammasome activation [72]. Furthermore, several studies have confirmed the existence of the ERS/TXNIP/NLRP3 inflammasome axis in multiple cells [73–76]. Increased ROS production through the NADPH oxidase pathway was shown to evoke ER stress in vivo, while enhanced unfolded protein response led to increased ROS production, exacerbating ER stress [77]. TXNIP, originally characterized as a thioredoxin (TRX)-binding protein that regulates the antioxidant function by modulating the release of Ca2+ from endoplasmic reticulum, is implicated in obesity and inflammation [79]. In response to ROS production, ERS induces the production of TXNIP, which is released from TRX and binds to NLRP3 to induce NLRP3 inflammasome activation [80]. The PERK and IRE1α pathways may mediate ERS-induced TXNIP production [81], which has been shown to activate the NLRP3 inflammasome in the liver [82]. In addition, blocking Ca2+ mobilization could inhibit the assembly and activation of the NLRP3 inflammasome complex [83]. The homologous CCAAT/enhancer binding protein (C/EBP), a transcription factor that modulates the release of Ca2+ from endoplasmic reticulum, has been shown to amplify NLRP3 inflammasome activation, thus linking ERS to activation of the NLRP3 inflammasome. After being activated, the NLRP3 inflammasome not only promotes IL-1β maturation following cleavage by caspase-1, but also induces mitochondrial cell death [84].

The NLRP3 inflammasome and inflammation

Inflammation plays a crucial role in the occurrence of ORKD, and rapid expansion of adipose tissue results in the aberrant production of pro-inflammatory adipokines, leading to metaflammation, a state of low-grade inflammation [2]. Metaflammation, triggered by an increased metabolic rate resulting from excessive nutrient consumption [85], has been shown to facilitate the progression of obesity-related diseases, especially renal disease [2]. Adipocytes play a key role in metaflammation propagation, and several pathways, including the c-junctional N-terminal kinase (JNK) pathway and the Toll receptor pathway, have been shown to be activated in subjects with obesity and implicated in the induction of inflammation in metabolic tissues [86, 87]. The pro-inflammatory adipokines TNF-α, IL-6 and IL-1β have been recognized as crucial mediators of adipose tissue inflammation [88, 89]. These pathways and cytokines lead to inflammatory cell recruitment and activation in metabolic tissues, resulting in excessive release of inflammatory cytokines and in the development of ORKD.

The caspase-1-IL-1β/IL-18 axis is the basis of NLRP3 inflammasome-induced inflammation in ORKD (Fig. 3), and release of the pro-inflammatory cytokines IL-1β and IL-18 is controlled by the NLRP3 inflammasome [90]. An animal study showed that the NLRP3 inflammasome-caspase-1-IL-1β/IL-18 axis plays a vital role in ORKD [91]. By regulating caspase-1 activation, the NLRP3 inflammasome can promote IL-1β and IL-18 maturation [45]. Moreover, IL-18 can promote the production of TNF-α, IL-1β and inter-cellular adhesion molecules via monocytes and macrophages, which can cause damage to the kidney [12]. However, in an HFD mice model, activation of the NLRP3 inflammasome was associated with ASC, pro-caspase 1, pro-IL-1β and pro-IL-18 but not with mature IL-1β and IL-18 [92]. Chi et al. identified the NLRP3 inflammasome/IL-1β-17 axis in renal inflammation and renal fibrosis [93], which may cause ORKD. However, the role of NLRP3 in ORKD is not necessarily limited to canonical (caspase/IL-1β/IL-18-dependent) inflammasome activation [90] because NLRP3 has additional, non-canonical roles in the development of ORKD via the TGF-β1 signalling pathway [94, 95], caspase-8 activation [96], and release of the pro-inflammatory high-mobility group box 1 [97].

Multiple inflammatory pathways may coexist in ORKD, and several studies have found that TLR4 can activate the NLRP3 inflammasome [98–100] (Fig. 3). In hepatocytes, NLRPS and TLR4 expression was up-regulated after lipopolysaccharide stimulation [101]. Moreover, CD36-mediated TLR4/6-IRAK4/1 signalling was shown to promote activation of the NLRP3 inflammasome in H9c2 cells [102]. Furthermore, He et al. found that TLR4 mediated NLRP3 inflammation in a mouse model of dextran sulphate sodium-induced colitis [100]. Taken together, these results suggest that the NLRP3 inflammasome activated by TLR4 is potentially the mechanism that leads to ORKD.

Interestingly, the Ca2+-dependent MAPK-JNK/NLRP3 inflammasome pathway may contribute to ORKD (Fig. 3). Chen et al. found that impairment of the Ca2+-dependent MAPK-JNK pathway suppressed NLRP3 inflammasome activation in bacteria [103] and demonstrated that JNK, a critical player in NLRP3 inflammasome activation, is a potential target of bacteria for manipulating inflammasomes. Moreover, activation of the MAPK-JNK pathway is necessary for complete activation of the NLRP3 inflammasome through ASC [104].

Collectively, activation of the NLRP3 inflammasome through multiple pathways may play an essential role in the initiation of inflammation in ORKD. However, the crosstalk among these pathways is not well understood and requires further investigation.
Conclusion and perspective

The aetiology and pathogenesis of ORKD are complicated. Oxidative stress, increased insulin and insulin resistance, and abnormal lipid metabolism are important risk factors of ORKD, but obesity and BMI are not. These ORKD risk factors appear to be closely related to the NLRP3 inflammasome, which is likely one of many mechanisms secondary to the structural and functional adaptions of nephrons to volume- and pressure-related stress on the filtration barrier. Furthermore, the mechanism by which the NLRP3 inflammasome promotes ORKD development remains incompletely understood, and inhibition of the NLRP3 inflammasome not only suppresses the accumulation of renal cholesterol [105], but also ameliorates renal injury caused by obesity [91, 106]. Therefore, targeting the NLRP3 inflammasome may provide a novel strategy for obesity-induced kidney injury therapy.

Acknowledgements

This work was supported by grants from the National Natural Science Foundation of China (General Program 81460142).

Conflicts of interest

All authors declare that there are no any ethical/legal conflicts involved associated with this article.

References

1. Freedman DS, Centers for Disease C, Prevention. Obesity - United States, 1988–2008. MMWR Surppl. 2011; 60: 73–7.
2. Snyder S, Turner GA, Turner A. Obesity-related kidney disease. Prim Care. 2014; 41: 875–93.
3. Kovesdy CP, Furth SL, Zoccali C, World Kidney Day Steering Committees. Obesity and kidney disease: hidden consequences of the epidemic. Am J Nephrol. 2017; 45: 283–91.
4. Pinto-Sietsma SJ, Navi G, Janssen WM, et al. PREVEND Study Group. A central body fat distribution is related to renal function impairment, even in lean subjects. Am J Kidney Dis. 2003; 41: 733–41.
5. Foster MC, Hwang SJ, Larson MG, et al. Overweight, obesity, and the development of stage 3 CKD: the Framingham Heart Study. Am J Kidney Dis. 2008; 52: 39–48.
6. Kramer H, Luke A, Bidani A, et al. Obesity and prevalent and incident CKD: the Hyperension Detection and Follow-Up Program. Am J Kidney Dis. 2005; 46: 587–94.
7. Chang A, Van Horn L, Jacobs DR Jr, et al. Lifestyle-related factors, obesity, and incident microalbuminuria: the CARDIA (Coronary Artery Risk Development in Young Adults) study. Am J Kidney Dis. 2013; 62: 267–75.
8. Lu JL, Molnar MZ, Naseer A, et al. Association of age and BMI with kidney function and mortality: a cohort study. Lancet Diabetes Endocrinol. 2015; 3: 704–14.
9. Vivante A, Golan E, Tzur D, et al. Body mass index in 1.2 million adolescents and risk for end-stage renal disease. Arch Intern Med. 2012; 172: 1644–50.
10. Lu JL, Kalantar-Zadeh K, Ma JZ, et al. Association of body mass index with outcomes in patients with CKD. J Am Soc Nephrol. 2014; 25: 2088–96.
11. Zhang C, Boini KM, Xia M, et al. Activation of Nod-like receptor protein 3 inflammasomes turns on podocyte injury and glomerular sclerosis in hyperhomocysteinemia. Hypertension. 2012; 60: 154–62.
12. Olu YY, Yang LQ. Roles of the NLRP3 inflammasome in the pathogenesis of diabetic nephropathy. Pharmacol Res. 2016; 114: 251–64.
13. Shahzad K, Bock F, Dong W, et al. Nlrp3 inflammasome activation in non-myeloid-derived cells aggravates diabetic nephropathy. Kidney Int. 2015; 87: 74–84.
14. Anders HJ. Of inflammasomes and alarmins: IL-1beta and IL-1alpha in kidney disease. J Am Soc Nephrol. 2016; 27: 2564–75.
15. Tsai YL, HuaKF, Chen A, et al. NLRP3 inflammasome: pathogenic role and potential therapeutic target for IgA nephropathy. Sci Rep. 2017; 7: 41123.
16. Mulay SR, Anders HJ. Crystal nephropathies: mechanisms of crystal-induced kidney injury. Nat Rev Nephrol. 2017; 13: 226–40.
17. Ross WR, McGill JB. Epidemiology of obesity and chronic kidney disease. Adv Chronic Kidney Dis. 2006; 13: 325–35.
18. D’Agati VD, Chagnac A, de Vries AP, et al. Obesity-related glomerulopathy: clinical and pathologic characteristics and pathogenesis. Nat Rev Nephrol. 2016; 12: 453–71.
19. Sharma K. The link between obesity and albuminuria: adiponectin and podocyte dysfunction. Kidney Int. 2009; 76: 145–8.
20. Wolf G, Ziyadeh FN. Leptin and renal fibrosis. Contrib Nephrol. 2006; 151: 175–83.
21. Ellington AA, Malik AR, Klee GG, et al. Association of plasma resistin with glomerular filtration rate and albuminuria in hypertensive adults. Hypertension. 2007; 50: 708–14.
22. Anders HJ, Andersen K, Stecher B. The intestinal microbiota, a leaky gut, and abnormal immunity in kidney disease. Kidney Int. 2013; 83: 1010–6.
23. Whaley-Conn A, Sowers JR. Obesity and kidney disease: from population to basic science and the search for new therapeutic targets. Kidney Int. 2017; 92: 313–23.
24. Altschuler-Keylin S, Kajimura S. Mitochondrial homeostasis in adipose tissue remodeling. Sci Signal. 2017; 10: http://doi: 10.1126/scisignal.aai9248.
25. Szeto HH, Liu S, Soong Y, et al. Protection of mitochondria prevents high-fat diet-induced glomerulopathy and proximal tubular injury. Kidney Int. 2016; 90: 997–1011.
26. Overbooom LH, de Vries AP, Gannevoort RT, et al. Fasting insulin modifies the relation between age and renal function. Nephrol Dial Transplant. 2007; 22: 1587–92.
27. Camara NO, Iskeli K, Kramer H, et al. Kidney disease and obesity: epidemiology, mechanisms and treatment. Nat Rev Nephrol. 2017; 13: 181–90.
28. Decleves AE, Sharma K. Obesity and kidney disease: differential effects of obesity on adipose tissue and kidney inflammation and fibrosis. Curr Opin Nephrol Hypertens. 2015; 24: 28–36.
29. He X, Guan B, Zhu L. Hemodynamics as measured with color doppler sonography in early-stage obesity-related nephropathy in children. J Ultrasound Med. 2017; 36: 1671–7.
30. Anastasio P, Viggiano D, Zacchia M, et al. Delay in renal hemodynamic response to a meal treat in severe obesity. *Nephron*. 2017; 136: 151–7.

31. Alobaidi R, Basu RK, Goldstein SL, et al. Sepsis-associated acute kidney injury. *Semin Nephrol*. 2015; 35: 2–11.

32. Yuan C, Liu C, Wang T, et al. Chikusetsu saponin Va ameliorates high fat diet-induced inflammation in adipose tissue of mice through inhibition of NLRP3 inflammasome activation and NF-kappaB signaling. *Oncotarget*. 2017; 8: 31023–40.

33. Abdul-Ghani MA, DeFronzo RA. Targeting renal gluco-statin system in metabolic syndrome and renal disease: pathophysiology and indicators. *Curr Hypertens Rep*. 2011; 13: 53–60.

34. Ye Y, Bajaj M, Yang HC, et al. SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Further augmented by the effects with sacubitril, a DPP4 inhibitor. *Cardiovasc Drugs Ther*. 2017; 31: 119–32.

35. Kamide K. Role of renin-angiotensin-aldosterone system in metabolic syndrome and obesity-related hypertension. *Curr Hypertens Rev*. 2014; [Epub ahead of print].

36. Wolf G, Ritz E. Combination therapy with ACE inhibitors and angiotensin II receptor blockers to halt progression of chronic renal disease: pathophysiology and indications. *Kidney Int*. 2005; 67: 799–812.

37. Bochud M, Nussberger J, Bovet P, et al. Plasma aldosterone is independently associated with the metabolic syndrome. *Hypertension*. 2006; 48: 239–45.

38. Cassis LA, Police SB, Yiannikouris F, et al. Local adipose tissue renin-angiotensin system. *Curr Hypertens Rep*. 2008; 10: 93–8.

39. Ruster C, Wolf G. The role of the renin-angiotensin-aldosterone system in obesity-related renal diseases. *Semin Nephrol*. 2013; 33: 44–53.

40. Ding W, Xu C, Wang B, et al. Rotenone attenuates renal injury in aldosterone-infused rats by inhibiting oxidative stress, mitochondrial dysfunction, and inflammasome activation. *Med Sci Monit*. 2015; 21: 3136–43.

41. Wang W, Luo R, Lin Y, et al. Aliskiren restores renal AQP2 expression during unilateral ureteral obstruction by inhibiting the protein signaling and fibrosis independent from the inflammasome. *J Biol Chem*. 2014; 289: 19571–84.

42. Che R, Yuan Y, Huang S, et al. Mitochondrial dysfunction in the pathophysiology of renal diseases. *Am J Physiol Renal Physiol*. 2014; 306: F367–78.

43. Weng W, Guo H, Xu C, et al. Mitochondrial reactive oxygen species-mediated NLRP3 inflammasome activation contributes to aldosterone-induced renal tubular cells injury. *Oncotarget*. 2016; 7: 17479–91.

44. Wang J, Wen Y, Lv LL, et al. Involvement of endoplasmic reticulum stress in angiotensin II-induced NLRP3 inflammasome activation in human renal proximal tubular cells in vitro. *Acta Pharmacol Sin*. 2015; 36: 821–30.

45. Bai M, Chen Y, Zhao M, et al. NLRP3 inflammasome activation contributes to aldosterone-induced podocyte injury. *Am J Physiol Renal Physiol*. 2017; 312: F556–F64. ajpregion.00332.2016.

46. Menon MC, Ross MJ. Epithelial-to-mesenchymal transition of tubular epithelial cells in renal fibrosis: a new twist on an old tale. *Kidney Int*. 2016; 90: 930–6.

47. Vilaysane A, Chun J, Seamone ME, et al. The NLRP3 inflammasome promotes renal inflammation and contributes to CKD. *J Am Soc Nephrol*. 2010; 21: 1732–44.

48. Zhang LL, Huang S, Ma XX, et al. Angiotensin(1–7) attenuated Angiotensin II-induced hepatocyte EMT by inhibiting NOX-derived H2O2-activated NLRP3 inflammasome/IL-1beta/Smad circuit. *Free Radic Biol Med*. 2016; 97: 531–43.

49. Granata S, Dalla Gassa A, Tomei P, et al. Mitochondria: a new therapeutic target in chronic kidney disease. *Nutr Metab*. 2015; 12: 49.

50. Lahera V, de Las Heras N, Lopez-Farre A, et al. Role of mitochondrial dysfunction in hypertension and obesity. *Curr Hypertens Rep*. 2017; 19: 11.

51. Mizushima N. Physiological functions of autophagy. Current topics in microbiology and immunology, 2009; 335: 71–84.

52. Yamamoto T, Takabatake Y, Takahashi A, et al. High-fat diet-induced lysosomal dysfunction and impaired autophagic flux contribute to lipotoxicity in the kidney. *J Am Soc Nephrol*. 2017; 28: 1534–51.

53. Tang C, Cai J, Dong Z. Mitochondrial dysfunction in obesity-related kidney disease: a novel therapeutic target. *Kidney Int*. 2016; 90: 930–3.

54. Bracey NA, Gershovich B, Chun J, et al. Mitochondrial NLRP3 protein induces reactive oxygen species to promote Smad
68. Liu QF, Ye JM, Deng ZY, et al. Ameliorating effect of Klotho on endoplasmic reticulum stress and renal fibrosis induced by unilateral ureteral obstruction. Iran J Kidney Dis. 2015; 9: 291–7.

69. Lee ES, Kim HM, Kang JS, et al. Oleic acid and N-acetylcysteine ameliorate diabetic nephropathy through reduction of oxidative stress and endoplasmic reticulum stress in a type 2 diabetic rat model. Nephrol Dial Transplant. 2016; 31: 391–400.

70. Guo H, Li H, Wang B, et al. Protective effects of glucagon-like peptide-1 analog on renal tubular injury in mice on high-fat diet. Cell Physiol Biochem. 2017; 41: 1113–24.

71. Wang C, Wu M, Arvapalli R, et al. Acetaminophen attenuates obesity-related renal injury through ER-mediated stress mechanisms. Cell Physiol Biochem. 2014; 33: 1139–48.

72. Fang L, Xie D, Wu X, et al. Involvement of endoplasmic reticulum stress in albuminuria induced inflammasome activation in renal proximal tubular cells. PLoS ONE. 2013; 8: e72344.

73. Li Y, Yang J, Chen MH, et al. Ilexgenin A inhibits endoplasmic reticulum stress and ameliorates endothelial dysfunction via suppression of TXNIP/NLRP3 inflammasome activation in an AMPK dependent manner. Pharmacol Res. 2015; 99: 101–15.

74. Chen W, Wang J, Luo Y, et al. Ginsenoside Rb1 and compound K improve insulin signaling and inhibit ER stress-associated NLRP3 inflammasome activation in adipose tissue. J Ginseng Res. 2016; 40: 351–8.

75. Li A, Zhang S, Li J, et al. Metformin and resveratrol inhibit Drp1-mediated mitochondrial fission and prevent ER stress-associated NLRP3 inflammasome activation in the adipose tissue of diabetic mice. Mol Cell Endocrinol. 2016; 434: 36–47.

76. Li Y, Li J, Li S, et al. Curcumin attenuates glutamate neurotoxicity in the hippocampus by suppression of ER stress-associated TXNIP/NLRP3 inflammasome activation in a manner dependent on AMPK. Toxicol Appl Pharmacol. 2015; 286: 53–63.

77. Lambeth JD, Neish AS. Nox enzymes and new thinking on reactive oxygen: a double-edged sword revisited. Ann Rev Pathol. 2014; 9: 119–45.

78. Zhou R, Tardivel A, Thorens B, et al. Thiorerodixin-interacting protein links oxidative stress to inflammasome activation. Nat Immunol. 2010; 11: 136–40.

79. Mohamed IN, Hafez SS, Fairaq A, et al. Thiorerodixin-interacting protein is required for endothelial NLRP3 inflammasome activation and cell death in a rat model of high-fat diet. Diabetologia. 2014; 57: 413–23.

80. Mittal M, Siddiqui MR, Tran K, et al. Reactive oxygen species in inflammation and tissue injury. Antioxid Redox Signal. 2014; 20: 1126–67.

81. Osłowski CM, Hara T, O'Sullivan-Murphy B, et al. Thiorerodixin-interacting protein mediates ER stress-induced beta cell death through initiation of the inflammasome. Cell Metab. 2012; 16: 265–73.

82. Lebeaupin C, Procs E, de Bieville CH, et al. ER stress induces NLRP3 inflammasome activation and hepatocyte death. Cell Death Dis. 2015; 6: e1879.

83. Murakami T, Ockinger J, Yu J, et al. Critical role for calcium mobilization in activation of the NLRP3 inflammasome. Proc Natl Acad Sci USA. 2012; 109: 11282–7.

84. Zhao Y, Li Q, Zhao W, et al. Astragaloside IV and cycloastragenol are equally effective in inhibition of endoplasmic reticulum stress-associated TXNIP/NLRP3 inflammasome activation in the endothelium. J Ethnopharmacol. 2015; 169: 210–8.

85. Solinas G, Karin M. JNK1 and IKKbeta: molecular links between obesity and metabolic dysfunction. FASEB J. 2010; 24: 2596–611.

86. Shi H, Kokoeva MV, Inouye K, et al. TLR4 links innate immunity and fatty acid-induced insulin resistance. J Clin Investig. 2006; 116: 3015–25.

87. Visser M, Bouter LM, McQuillan GM, et al. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999; 282: 2131–5.

88. Uysal KT, Wiesbrock SM, Marino MW, et al. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature. 1997; 389: 610–4.

89. Hatanaka GL, Sharng IS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993; 259: 87–91.

90. Lorenz G, Darisipudi MN, Anders HJ. Canonical and non-canonical effects of the NLRP3 inflammasome in kidney inflammation and fibrosis. Nephrol Dial Transplant. 2014; 29: 41–8.

91. Chiassà F, Couturier-Mailiard A, Benetti E, et al. Targeting the NLRP3 inflammasome to reduce diet-induced metabolic abnormalities in mice. Mol Med. 2015; [Epub ahead of print].

92. Solini A, Menini S, Rossi C, et al. The purinergic 2X7 receptor participates in renal inflammation and injury induced by high-fat diet: possible role of NLRP3 inflammasome activation. J Pathol. 2013; 231: 342–33.

93. Chi HH, Hua KF, Lin YC, et al. IL-36 signaling facilitates activation of the NLRP3 inflammasome and IL-23/IL-17 axis in renal inflammation and fibrosis. J Am Soc Nephrol. 2017; 28: 2022–37.

94. Wang W, Wang X, Chun J, et al. Inflammasome-independent NLRP3 augments TGF-beta signaling in kidney epithelium. J Immunol. 2013; 190: 1239–49.

95. Lech M, Lorenz G, Kukarni OP, et al. NLRP3 and ASC suppress lupus-like autoimmunity by driving the immunosuppressive effects of TGF-beta receptor signalling. Ann Rheum Dis. 2015; 74: 2224–35.

96. Chung H, Viaysane A, Lau A, et al. NLRP3 regulates a non-canonical platform for caspase-8 activation during epithelial cell apoptosis. Cell Death Differ. 2016; 23: 1331–46.

97. Andersen K, Eltirich N, Lichtneker J, et al. The NLRP3/ASC inflammasome promotes T-cell-dependent immune complex glomerulonephritis by canonical and non-canonical mechanisms. Kidney Int. 2014; 86: 965–78.

98. Kong F, Ye B, Cao J, et al. Curcumin represses NLRP3 inflammasome activation via TLR4/MyD88/IRAK4/1 signaling and P2X7R signaling in PMA-induced macrophages. Front Pharmacol. 2016; 7: 369.

99. Palova-Jelinkova L, Danova K, Drasarova H, et al. Pepsin digest of wheat gliadin fraction increases production of IL-1beta via TLR4/MyD88/TRIF MAPK/NF-kappaB and P2X7R signaling pathway and an NLRP3 inflammasome activation. PLoS ONE. 2013; 8: e62426.

100. He X, Wei Z, Wang J, et al. Alpinetin attenuates inflammatory responses by suppressing TLR4 and NLRP3 signaling pathways in DSS-induced acute colitis. Sci Rep. 2016; 6: 28370.

101. Zhang F, Jin H, Wu L, et al. Ligustazine disrupts lipopolysaccharide-activated NLRP3 inflammasome pathway associated with inhibition of Toll-like receptor 4 in hepatocytes. Biomed Pharmacother. 2016; 78: 204–9.

102. Kang L, Zhang DM, Ma CH, et al. Cinnamaldehyde and allopurinol reduce fracture-induced cardiac inflammation and fibrosis by attenuating CD36-mediated TLR4/6-IRAK4/1 signaling to suppress...
NLRP3 inflammasome activation. Sci Rep. 2016; 6: 27460.

103. Chen H, Yang D, Han F, et al. The bacterial T6SS effector EvpP prevents NLRP3 inflammasome activation by inhibiting the Ca^{2+}-dependent MAPK-Jnk pathway. Cell Host Microbe. 2017; 21: 47–58.

104. Okada M, Matsuzawa A, Yoshimura A, et al. The lysosome rupture-activated TAK1-JNK pathway regulates NLRP3 inflammasome activation. J Biol Chem. 2014; 289: 32926–36.

105. Bakker PJ, Butter LM, Kors L, et al. Nlrrp3 is a key modulator of diet-induced nephropathy and renal cholesterol accumulation. Kidney Int. 2014; 85: 1112–22.

106. Collino M, Benetti E, Rogazzo M, et al. Reversal of the deleterious effects of chronic dietary HFCS-55 intake by PPAR-delta agonism correlates with impaired NLRP3 inflammasome activation. Biochem Pharmacol. 2013; 85: 257–64.